GE Healthcare working ‘two to three years’ ahead anticipating manufacturing advances

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Smshoot)
(Image: Getty/Smshoot)

Related tags: Ge healthcare, G-CON

The rapid evolution of cell and gene therapy technology is leading GE Healthcare to explore partnerships to meet increasing manufacturing demand, according to the company's enterprise solutions leader.

In January, GE Healthcare and G-CON announced​ that they would combine capabilities to offer prefabricated manufacturing platforms. The partnership arrived shortly after GE Healthcare worked with Lonza​ to set up a biologics facility in China.

Greg Crescenzi, enterprise solutions leader for cell & gene therapy at GE Healthcare, told us that partnerships are an important strategy for contract manufacturing organisations (CMOs) to meet demand.

Crescenzi explained that 40% year-on-year growth seen in the sector throws up new challenges, including how to supply the industry when related technology is developing rapidly.

“We must anticipate what therapeutic manufacturing models will look like in two to three years and design tools and pursue partnerships that will allow us to meet manufacturing needs,”​ he explained.

According to Crescenzi, this was the motivation behind the partnership with G-CON, by enabling a unique offering of a single, ready-made facility to provide the materials needed to progress drug candidates from the clinical trial stage to commercialisation.

“It provides customers with an entire cleanroom infrastructure from a single source and will improve and accelerate cell therapy and viral manufacturing on a good manufacturing practice (GMP) scale,”​ he said.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 20-Jan-2020 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us


View more